αC IN, αC OUT-that's what it's all about.

Abstract

Despite recent successes in drug development, metastatic melanoma remains a challenging disease. Efforts to design new targeted therapies as well as improve efficacy with combinations of existing inhibitors have yielded increases in progression free and overall survival. However, as with many targeted therapies across the cancer spectrum, habitual treatment often leads to drug resistance and progression necessitating alternative treatment regimens. This article is protected by copyright. All rights reserved.